BridgeBio Encaleret NDA Accepted, PDUFA May 2027

BridgeBio Pharma (BBIO) announced on July 22, 2026 that the FDA accepted for filing its New Drug Application for encaleret, an oral therapy for autosomal dominant hypocalcemia type 1 (ADH1). The FDA assigned a PDUFA target action date of May 8, 2027, and is not currently planning an advisory committee meeting.

What ADH1 is

ADH1 is an ultra-rare genetic disorder caused by gain-of-function mutations in the calcium-sensing receptor gene. The mutation causes the body to inappropriately suppress parathyroid hormone production, leading to low blood calcium, excessive urinary calcium excretion, kidney damage, muscle cramps, and seizures. There are no FDA-approved treatments specifically for ADH1. More than 2,100 individuals have been diagnosed in the U.S. since October 2023, a number that likely undercounts the true prevalence given how often the condition goes unrecognized.

Patients typically cycle through multiple specialists before anyone connects their symptoms to ADH1. Current management relies on calcium and active vitamin D supplements, which can worsen the urinary calcium excretion that drives kidney damage over time.

The drug and the trial

Encaleret is an oral small molecule that selectively modulates the calcium-sensing receptor. The NDA is based on the Phase 3 CALIBRATE trial, which met all prespecified primary and key secondary efficacy endpoints. The trial showed encaleret normalized key markers of calcium-sensing receptor-driven disease biology without the need for calcium and vitamin D supplements, with a favorable safety profile.

Additional data presented at the European Congress of Endocrinology 2026 and the Endocrine Society annual meeting showed simultaneous restoration of blood and urine calcium levels and restoration of physiologic parathyroid hormone production.

Encaleret has received Fast Track Designation and Orphan Drug Designation in the U.S., European Union, and Japan. BridgeBio also plans to submit a European Marketing Authorization Application in the second half of 2026.

Why the no-adcom signal matters

The FDA’s decision not to hold an advisory committee meeting is a positive signal. Advisory committees are convened when the FDA wants outside expert input on questions about efficacy, safety, or trial design. Skipping adcom typically means the agency is comfortable with the data package and does not see issues requiring external deliberation.

For a first-in-class therapy in an ultra-rare disease with no approved treatments, this suggests the CALIBRATE data is clean enough that the FDA does not anticipate controversy. It does not guarantee approval, but it removes a potential hurdle.

BBIO closed at $82.93 on July 22 with a market cap of approximately $16.2 billion. BridgeBio calls encaleret a potential blockbuster, meaning $1 billion-plus in annual revenue. That is a stretch for 2,100 diagnosed patients, but the count is growing and no competitor exists. At $300,000 to $500,000 per patient annually, the diagnosed population alone could support $630 million to $1.05 billion. The RECLAIM-HP trial in chronic hypoparathyroidism would add to that.

What to watch next

The risk factor is the 10-month wait until the May 2027 PDUFA date. During that window, the FDA could reverse its no-adcom position if review questions emerge. BridgeBio is also enrolling CALIBRATE-PEDS, a Phase 2/3 study in pediatric ADH1.

For context on FDA drug application reviews, see our coverage of Madrigal’s resmetirom PDUFA.

What It Means for the Trade

The filing acceptance with a May 2027 PDUFA and no adcom converts encaleret from a pipeline story into a dated regulatory binary with a favorable-looking posture. The no-adcom signal is doing real analytical work: for a first-in-class molecule against a gain-of-function receptor mutation — the exact category where mechanism questions usually draw advisory scrutiny — the FDA’s comfort suggests CALIBRATE’s data package is clean. The endpoint story is also unusually strong for an ultra-rare endocrine drug: encaleret normalized disease markers without calcium and vitamin D supplementation, and the follow-up data showed physiologic PTH restoration — meaning the drug doesn’t just manage the biochemistry, it re-regulates the broken feedback loop. That is the kind of mechanism-complete result that supports both approval and a premium launch narrative.

The commercial math is where skepticism belongs, and the honest framing is that “blockbuster” is management enthusiasm. The arithmetic: roughly 2,100 diagnosed U.S. patients, growing as recognition improves, at an assumed $300,000-$500,000 per patient annually puts the diagnosed-only opportunity at $630 million to $1.05 billion — blockbuster-adjacent only if pricing hits the top of the range and diagnosis growth compounds. The RECLAIM-HP expansion into chronic hypoparathyroidism is the volume leg that makes the franchise math work: chronic hypoPT is a far larger post-thyroidectomy population, and a CaSR modulator with ADH1’s data package could move into it with regulatory momentum. For a $16.2 billion market cap, encaleret is one of several value legs — but it’s the one with the nearest dated catalyst.

Mechanism and Market Context

The pathophysiology explains why the drug is mechanistically elegant. ADH1 is gain-of-function in the calcium-sensing receptor — the receptor is too sensitive, so it “reads” normal calcium as high and suppresses PTH secretion, producing hypocalcemia while paradoxically driving urinary calcium wasting (the receptor also gates renal calcium handling). Standard supplementation actively feeds the renal loss because the oversensitive receptor keeps dumping calcium into urine — the current standard of care worsens the kidney-damage pathway over time. Encaleret is a negative allosteric modulator of the same receptor: dialing its sensitivity back toward normal restores PTH production, corrects blood calcium, and stops the urinary wasting simultaneously. The clinical data showing blood and urine calcium both normalizing is exactly what a correct mechanism predicts, which is why the FDA’s comfort is credible.

The commercial setup has the classic ultra-rare profile: no approved competitor, a diagnostic funnel that is the real growth constraint (patients cycle through specialists for years before anyone tests the CaSR gene), and a specialist prescriber base in endocrinology that is small, reachable, and mechanism-literate. Orphan exclusivity plus the ultra-rare framing supports premium pricing; the underdiagnosed prevalence is the growth story to track.

Risks and What Could Go Wrong

1. Review friction at month eight: the FDA reversing to an adcom or issuing a major amendment extends the clock — rare, but it converts a May 2027 catalyst into a 2028 one.
2. Pricing reality lands below the $300k-$500k assumption, and the “blockbuster” framing collides with a diagnosed population measured in the low thousands.
3. RECLAIM-HP in chronic hypoPT is the volume leg, and it is unproven — a hypoPT setback caps encaleret at ultra-orphan economics.
4. Concentration optics: BridgeBio is running Attruby’s launch, infigratinib’s NDA, and encaleret’s review simultaneously — execution bandwidth across three launches is the quiet operational risk.

Position read: encaleret is a high-base-rate approval setup in a no-competition indication with dated catalysts — the kind of asset that quietly adds sum-of-parts value while the market focuses on Attruby. Watch for label language on supplement discontinuation; that detail is the commercial thesis in regulatory form.

Source: BridgeBio press release | StockTitan 8-K filing